Top

Published in:

01-08-2013 | Review Article

Do proton pump inhibitors protect against cancer progression in GERD?

Authors: Tomoharu Miyashita, Furhawn A. Shah, John W. Harmon, Guy P. Marti, Daisuke Matsui, Koichi Okamoto, Isamu Makino, Hironori Hayashi, Katsunobu Oyama, Hisatoshi Nakagawara, Hidehiro Tajima, Hideto Fujita, Hiroyuki Takamura, Manabu Murakami, Itasu Ninomiya, Hirohisa Kitagawa, Sachio Fushida, Takashi Fujimura, Tetsuo Ohta

Published in: Surgery Today | Issue 8/2013

Abstract

Gastro-duodenal content reflux from gastro-esophageal reflux disease (GERD) induces the inflammation–metaplasia–dysplasia–adenocarcinoma sequence. Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, which are widely used for treating GERD and peptic ulcer-associated acid-secreting diseases. The effect of PPI therapy on esophageal carcinogenesis remains unclear. While some studies suggest PPIs result in a significant reduction in the risk of developing dysplasia and adenocarcinoma in patients with Barrett’s esophagus, others suggest that PPIs have no effect. Recent studies have revealed that PPIs can exert anti-inflammatory effects such as anti-oxidant properties and immunomodulatory effects through their interactions with neutrophils, monocytes, endothelial and epithelial cells. In addition, PPIs have the ability to prevent adhesion molecule binding in malignant cells and suppress metastasis. This article reviews the role of PPIs in esophageal carcinogenesis and their use as antitumor agents.

Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998;48:6–29.PubMedCrossRef

Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett’s oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer. 2010;10:87–101.PubMedCrossRef

Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.PubMedCrossRef

Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett’s esophagus: effect of medical acid suppression and nissen fundoplication. J Gastrointest Surg. 1998;2:333–41.PubMedCrossRef

Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut. 1999;44:598–602.PubMedCrossRef

Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Ritter MP, et al. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J Gastrointest Surg. 1998;2:260–8.PubMedCrossRef

Quinlan JM, Colleypriest BJ, Farrant M, Tosh D. Epithelial metaplasia and the development of cancer. Biochim Biophys Acta. 2007;1776:10–21.PubMed

Miwa K, Sahara H, Segawa M, Kinami S, Sato T, Miyazaki I, et al. Reflux of duodenal or gastro-duodenal contents induces esophageal carcinoma in rats. Int J Cancer. 1996;67:269–74.PubMedCrossRef

Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst. 2003;95:1404–13.PubMedCrossRef

10.

Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett’s esophagus. Gastroenterology. 2007;133:403–11.PubMedCrossRef

11.

Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology 2007;133:34–41 (quiz 311).

12.

Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez NP, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity–carcinogenesis link. Best Pract Res Clin Endocrinol Metab. 2008;22:659–69.PubMedCrossRef

13.

Kahrilas PJ. Cigarette smoking and gastroesophageal reflux disease. Dig Dis. 1992;10:61–71.PubMedCrossRef

14.

Stolte M. Fundic gland polyps: a rare, innocuous, and reversible disturbance. Gastroenterology. 1993;105:1590–1.PubMedCrossRef

15.

Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–8.

16.

Raghunath AS, O’Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22(Suppl 1):55–63.PubMedCrossRef

17.

Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–53.PubMedCrossRef

18.

Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179:319–26.PubMed

19.

McCarthy DM. Adverse effects of proton pump inhibitor drugs: clues and conclusions. Curr Opin Gastroenterol. 2010;26:624–31.PubMedCrossRef

20.

Geller JL, Adams JS. Proton pump inhibitor therapy and hip fracture risk. JAMA. 2007;297:1429 (author reply 1429–30).

21.

Richards JB, Goltzman D. Proton pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008;179:306–7.PubMed

22.

Lapenna D, de Gioia S, Ciofani G, Festi D, Cuccurullo F. Antioxidant properties of omeprazole. FEBS Lett. 1996;382:189–92.PubMedCrossRef

23.

Blandizzi C, Fornai M, Colucci R, Natale G, Lubrano V, Vassalle C, et al. Lansoprazole prevents experimental gastric injury induced by non-steroidal anti-inflammatory drugs through a reduction of mucosal oxidative damage. World J Gastroenterol. 2005;11:4052–60.PubMed

24.

Simon WA, Sturm E, Hartmann HJ, Weser U. Hydroxyl radical scavenging reactivity of proton pump inhibitors. Biochem Pharmacol. 2006;71:1337–41.PubMedCrossRef

25.

Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, Akagiri S, et al. Lansoprazole, a proton pump inhibitor, mediates anti-inflammatory effect in gastric mucosal cells through the induction of heme oxygenase-1 via activation of NF-E2-related factor 2 and oxidation of kelch-like ECH-associating protein 1. J Pharmacol Exp Ther. 2009;331:255–64.PubMedCrossRef

26.

Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil–endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81.PubMedCrossRef

27.

Handa O, Yoshida N, Fujita N, Tanaka Y, Ueda M, Takagi T, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflamm Res. 2006;55:476–80.PubMedCrossRef

28.

Maity P, Bindu S, Choubey V, Alam A, Mitra K, Goyal M, et al. Lansoprazole protects and heals gastric mucosa from non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy by inhibiting mitochondrial as well as Fas-mediated death pathways with concurrent induction of mucosal cell renewal. J Biol Chem. 2008;283:14391–401.PubMedCrossRef

29.

Ohta T, Tajima H, Yachie A, Yokoyama K, Elnemr A, Fushida S, et al. Activated lansoprazole inhibits cancer cell adhesion to extracellular matrix components. Int J Oncol. 1999;15:33–9.PubMed

30.

Milito AD, Marino ML, Fais S. A rationale for the use of proton pump inhibitors as antineoplastic agents. Curr Pharm Des. 2012;18:1395–406.PubMedCrossRef

31.

Miwa K, Fujimura T, Hasegawa H, Kosaka T, Miyata R, Miyazaki I, et al. Is bile or are pancreaticoduodenal secretions related to gastric carcinogenesis in rats with reflux through the pylorus? J Cancer Res Clin Oncol. 1992;118:570–4.PubMedCrossRef

32.

Miwa K, Segawa M, Takano Y, Matsumoto H, Sahara H, Yagi M, et al. Induction of oesophageal and forestomach carcinomas in rats by reflux of duodenal contents. Br J Cancer. 1994;70:185–9.PubMedCrossRef

33.

Miwa K, Hattori T, Miyazaki I. Duodenogastric reflux and foregut carcinogenesis. Cancer. 1995;75:1426–32.PubMedCrossRef

34.

Oberg S, Lord RV, Peters JH, Chandrasoma P, Theisen J, Hagen JA, et al. Is adenocarcinoma following esophagoduodenostomy without carcinogen in the rat reflux-induced? J Surg Res. 2000;91:111–7.PubMedCrossRef

35.

Goldstein SR, Yang GY, Curtis SK, Reuhl KR, Liu BC, Mirvish SS, et al. Development of esophageal metaplasia and adenocarcinoma in a rat surgical model without the use of a carcinogen. Carcinogenesis. 1997;18:2265–70.PubMedCrossRef

36.

Byrnes CK, Bahadursingh A, Akhter N, Parinandi NL, Natarajan V, Montgomery E, et al. Duodenal reflux produces hyperproliferative epithelial esophagitis—a possible precursor to esophageal adenocarcinoma in the rat. J Gastrointest Surg. 2003;7:172–80.PubMedCrossRef

37.

Pera M, Brito MJ, Poulsom R, Riera E, Grande L, Hanby A, et al. Duodenal-content reflux esophagitis induces the development of glandular metaplasia and adenosquamous carcinoma in rats. Carcinogenesis. 2000;21:1587–91.PubMedCrossRef

38.

Macke RA, Nason KS, Mukaisho K, Hattori T, Fujimura T, Sasaki S, et al. Barrett’s esophagus and animal models. Ann N Y Acad Sci. 2011;1232:392–400.PubMedCrossRef

39.

Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg. 1995;222:525–31 (discussion 31–3).

40.

Osugi H, Higashino M, Kaseno S, Takada N, Takemura M, Ueno M, et al. Ambulatory intraesophageal bilirubin monitoring in Japanese patients with gastroesophageal reflux. J Gastroenterol. 2002;37:697–702.PubMedCrossRef

41.

Kumagai H, Mukaisho K, Sugihara H, Miwa K, Yamamoto G, Hattori T. Thioproline inhibits development of esophageal adenocarcinoma induced by gastroduodenal reflux in rats. Carcinogenesis. 2004;25:723–7.PubMedCrossRef

42.

Sasaki S, Miwa K, Fujimura T, Oba M, Miyashita T, Kinami S. Ingestion of thioproline suppresses rat esophageal adenocarcinogenesis caused by duodenogastroesophageal reflux. Oncol Rep. 2007;18:1443–9.PubMed

43.

Araki Y, Mukaisyo K, Sugihara H, Fujiyama Y, Hattori T. Detection of N-nitroso-bile acids at 285 nm in reverse-phase HPLC. J Sep Sci. 2008;31:2827–30.PubMedCrossRef

44.

Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol. 2006;12:1336–45.PubMed

45.

Miyashita T, Ohta T, Fujimura T, Ninomiya I, Fushida S, Hattori T, et al. Duodenal juice stimulates oesophageal stem cells to induce Barrett’s oesophagus and oesophageal adenocarcinoma in rats. Oncol Rep. 2006;15:1469–75.PubMed

46.

Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, et al. Cytogenetic characterization and gene expression profiling in the rat reflux-induced esophageal tumor model. J Thorac Cardiovasc Surg. 2007;133:763–9.PubMedCrossRef

47.

Miyashita T, Shah FA, Marti GP, Wang J, Bonde P, Gibson MK, et al. Rabeprazole impedes the development of reflux-induced esophageal cancer in a surgical rat model. Dig Dis Sci. 2011;56:1309–14.PubMedCrossRef

48.

Nasr AO, Dillon MF, Conlon S, Downey P, Chen G, Ireland A, et al. Acid suppression increases rates of Barrett’s esophagus and esophageal injury in the presence of duodenal reflux. Surgery. 2012;151:382–90.PubMedCrossRef

49.

Moore KH, Barry P, Burn J, Falk G. Adenocarcinoma of the rat esophagus in the presence of a proton pump inhibitor: a pilot study. Dis Esophagus. 2001;14:17–22.PubMedCrossRef

50.

Hao J, Zhang B, Liu B, Lee M, Hao X, Reuhl KR, et al. Effect of alpha-tocopherol, N-acetylcysteine and omeprazole on esophageal adenocarcinoma formation in a rat surgical model. Int J Cancer. 2009;124:1270–5.PubMedCrossRef

51.

Dadabhai A, Friedenberg FK. Rabeprazole: a pharmacologic and clinical review for acid-related disorders. Expert Opin Drug Saf. 2009;8:119–26.PubMedCrossRef

52.

De Jonge PJ, Siersema PD, Van Breda SG, Van Zoest KP, Bac DJ, Leeuwenburgh I, et al. Proton pump inhibitor therapy in gastro-oesophageal reflux disease decreases the oesophageal immune response but does not reduce the formation of DNA adducts. Aliment Pharmacol Ther. 2008;28:127–36.PubMedCrossRef

53.

Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48:322–8.PubMedCrossRef

54.

Nochi S, Yokoyama Y, Narukawa M, Ebine K, Murahashi M, Kawakami Y, et al. Mechanism of inhibition of H+, K(+)-ATPase by sodium 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (E3810). Chem Pharm Bull (Tokyo). 1996;44:552–8.CrossRef

55.

Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118:S9–31.PubMedCrossRef

56.

Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol. 2001;13(Suppl 1):S35–41.PubMed

57.

El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2004;99:1877–83.PubMedCrossRef

58.

Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Gastroenterology. 2010;138:2260–6.PubMedCrossRef

59.

Sharma P. Barrett esophagus: will effective treatment prevent the risk of progression to esophageal adenocarcinoma? Am J Med. 2004;117 Suppl 5A:79S–85S.

60.

Fitzgerald RC. Review article: Barrett’s oesophagus and associated adenocarcinoma—a UK perspective. Aliment Pharmacol Ther. 2004;20(Suppl 8):45–9.PubMedCrossRef

61.

Chang EY, Morris CD, Seltman AK, O’Rourke RW, Chan BK, Hunter JG, et al. The effect of antireflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg. 2007;246:11–21.PubMedCrossRef

62.

Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–9.PubMedCrossRef

63.

Schwartz MA. Signaling by integrins: implications for tumorigenesis. Cancer Res. 1993;53:1503–6.PubMed

64.

Nagaya H, Satoh H, Kubo K, Maki Y. Possible mechanism for the inhibition of gastric (H⁺ + K⁺)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther. 1989;248:799–805.PubMed

65.

Nagaya H, Satoh H, Maki Y. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther. 1990;252:1289–95.PubMed

66.

Norimasa Y, Toshikazu Y. Proton pump inhibitors have various function beyond acid suppression (in Japanese). Tokyo: Shindann to Chiryousya; 2009.

67.

McCarty MF, Whitaker J. Manipulating tumor acidification as a cancer treatment strategy. Altern Med Rev. 2010;15:264–72.PubMed

68.

Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis. 1997;15:382–92.PubMedCrossRef

69.

Ohta T, Amaya K, Yi S, Kitagawa H, Kayahara M, Ninomiya I, et al. Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol. 2003;23:593–8.PubMed

70.

Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem. 1997;272:22438–46.PubMedCrossRef

71.

Koury SI, Stone CK, La Charite DD. Omeprazole and the development of acute hepatitis. Eur J Emerg Med. 1998;5:467–9.PubMedCrossRef

72.

Yip D, Kovac S, Jardine M, Horvath J, Findlay M. Omeprazole-induced interstitial nephritis. J Clin Gastroenterol. 1997;25:450–2.PubMedCrossRef

73.

Schonhofer PS, Werner B, Troger U. Ocular damage associated with proton pump inhibitors. BMJ. 1997;314:1805.PubMedCrossRef

74.

Jalving M, Koornstra JJ, Gotz JM, van der Waaij LA, de Jong S, Zwart N, et al. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol. 2003;15:1229–33.PubMedCrossRef

75.

Wu TT, Kornacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol. 1998;22:293–8.PubMedCrossRef

76.

Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 2011;60:624–30.PubMedCrossRef

77.

Robinson M. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther. 1999;13(Suppl 5):5–10.PubMedCrossRef

78.

Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16:2323–30.PubMedCrossRef

79.

O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778–81.PubMedCrossRef

80.

Ohta T, Hashimoto T, Murai J, Kimura H. Influence of proton pump inhibitor on bone metabolism marker. J New Rem Clin. 2008;57:1341–5.

81.

Sheraly AR, Lickorish D, Sarraf F, Davies JE. Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv. 2009;6:192–8.PubMedCrossRef

82.

Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391–8.PubMedCrossRef

83.

Yamanaka Y, Mammoto T, Kita T, Kishi Y. A study of 13 patients with gastric tube in place after esophageal resection: use of omeprazole to decrease gastric acidity and volume. J Clin Anesth. 2001;13:370–3.PubMedCrossRef

84.

Hauben M, Horn S, Reich L, Younus M. Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools. Int J Infect Dis. 2007;11:417–22.PubMedCrossRef

85.

Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56 (quiz 57).

86.

Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33–8.PubMed

87.

Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6:105–8.PubMedCrossRef

88.

Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103:2308–13.PubMedCrossRef

89.

Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–95.PubMedCrossRef

Title: Do proton pump inhibitors protect against cancer progression in GERD?
Authors: Tomoharu Miyashita
Furhawn A. Shah
John W. Harmon
Guy P. Marti
Daisuke Matsui
Koichi Okamoto
Isamu Makino
Hironori Hayashi
Katsunobu Oyama
Hisatoshi Nakagawara
Hidehiro Tajima
Hideto Fujita
Hiroyuki Takamura
Manabu Murakami
Itasu Ninomiya
Hirohisa Kitagawa
Sachio Fushida
Takashi Fujimura
Tetsuo Ohta
Publication date: 01-08-2013
Publisher: Springer Japan
Published in: Surgery Today / Issue 8/2013
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-012-0395-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Do proton pump inhibitors protect against cancer progression in GERD?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2013

Feasibility of laparoscopic gastrectomy for advanced gastric cancer with positive peritoneal cytology

Totally extraperitoneal inguinal hernia repair in patients on antithrombotic therapy: a retrospective analysis

Significant improvement of chronic pain by Pregabalin after thoracotomy: report of four cases

Hand-assisted laparoscopic splenectomy for thrombocytopenia in patients with cirrhosis

Intraoperative mechanical and chemical pleurodesis with 50 % glucose solution for secondary spontaneous pneumothorax in patients with pulmonary emphysema

Resection of intralobar pulmonary sequestration after coil embolization of aberrant arteries: report of a case